Who are rhPTH (1-84)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Teriparatide (Forteo), Teriparatide Pen Injector, Teriparatide (rDNA origin), Parathyroid Hormone (PTH), teriparatide and raloxifene, teriparatide and alendronate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhpth-1-84.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

rhPTH (1-84) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rhPTH (1-84) (rhPTH (1-84)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PTH1 receptor agonist. Area: Endocrinology.

marketed PTH1 receptor agonist PTH1 receptor Endocrinology Biologic Live · refreshed every 30 min

Target snapshot

rhPTH (1-84) (rhPTH (1-84)) — Shire. rhPTH (1-84) is a recombinant human parathyroid hormone that binds to PTH1 receptors on bone cells to stimulate bone formation and increase serum calcium and phosphate levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rhPTH (1-84) TARGET	rhPTH (1-84)	Shire	marketed	PTH1 receptor agonist	PTH1 receptor
Teriparatide (Forteo)	Teriparatide (Forteo)	M.D. Anderson Cancer Center	marketed	Parathyroid hormone analog	PTH1 receptor (parathyroid hormone 1 receptor)
Teriparatide Pen Injector	Teriparatide Pen Injector	University of Edinburgh	marketed	Parathyroid hormone analog	PTH1 receptor
Teriparatide (rDNA origin)	Teriparatide (rDNA origin)	Bio Sidus SA	marketed	Parathyroid hormone analog	PTH1 receptor (PTHR1)
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)
teriparatide and raloxifene	teriparatide and raloxifene	Medical University of Vienna	marketed	Combination therapy: PTH analog and selective estrogen receptor modulator (SERM)	PTH1 receptor (teriparatide); estrogen receptor alpha and beta (raloxifene)
teriparatide and alendronate	teriparatide and alendronate	Medical University of Vienna	marketed	Combination therapy: PTH analog + bisphosphonate	PTH1 receptor (teriparatide); farnesyl pyrophosphate synthase (alendronate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PTH1 receptor agonist class)

Shire · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhPTH (1-84) — Competitive Intelligence Brief. https://druglandscape.com/ci/rhpth-1-84. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing